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Distinct epigenetic programs regulate cardiac
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heart in vivo
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Epigenetic mechanisms and transcription factor networks essential for differentiation of
cardiac myocytes have been uncovered. However, reshaping of the epigenome of these
terminally differentiated cells during fetal development, postnatal maturation, and in disease
remains unknown. Here, we investigate the dynamics of the cardiac myocyte epigenome
during development and in chronic heart failure. We ﬁnd that prenatal development and
postnatal maturation are characterized by a cooperation of active CpG methylation and
histone marks at cis-regulatory and genic regions to shape the cardiac myocyte tran-
scriptome. In contrast, pathological gene expression in terminal heart failure is accompanied
by changes in active histone marks without major alterations in CpG methylation and
repressive chromatin marks. Notably, cis-regulatory regions in cardiac myocytes are sig-
niﬁcantly enriched for cardiovascular disease-associated variants. This study uncovers dis-
tinct layers of epigenetic regulation not only during prenatal development and postnatal
maturation but also in diseased human cardiac myocytes.
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The heart is the ﬁrst organ to develop during embryogen-esis1. The general principles of cardiac development havebeen studied in great detail on a morphological and
molecular basis. These studies have identiﬁed key signaling events
and transcription factor networks that are involved in the spe-
ciﬁcation and differentiation of cardiac myocytes (CMs)1–6. Many
of these transitions involve changes of gene expression. This in
turn is regulated by epigenetic processes including CpG methy-
lation (mCpG) and histone modiﬁcations. However, the detailed
epigenetic processes involved in maturation from fetal to adult
CMs and in cardiac disease leading to terminal heart failure have
not been fully uncovered, yet.
Epigenetic studies in human hearts have identiﬁed altered
mCpG in chronic heart failure7,8. Owing to technical restrictions,
these studies were performed in heart tissue and therefore the
affected cell type(s) could not be identiﬁed. Epigenetic mechan-
isms are highly cell-type-speciﬁc requiring cell separation tech-
niques to determine epigenomic features in a speciﬁc cell type,
especially when keeping in mind that the cellular composition of
the human heart is highly dynamic. Previous studies in mice have
used enzymatic dissociation by the Langendorff technique9,10 or
additional puriﬁcation of dissociated cardiac cells by ﬂow cyto-
metry11,12 to study cell-type-speciﬁc features of the CM tran-
scriptome and epigenome, respectively. Puriﬁcation of CM nuclei
by ﬂuorescence-assisted sorting has led to the identiﬁcation of
cell-type-speciﬁc mCpG and histone modiﬁcation signatures in
CMs during mouse heart development and maturation11. Based
on this method13,14, we used a nuclear staining strategy to isolate
CM nuclei from intact prenatal and postnatal human heart tissue
and subjected these nuclei to comprehensive analysis of the epi-
genome during prenatal development, postnatal maturation, and
in heart failure.
Here we describe the human CM epigenome during prenatal
development and postnatal maturation of the heart from infant to
adult age and in terminal failure. We ﬁnd that during normal
lifespan of CMs gene regulation is mainly orchestrated by
dynamic mCpG and canonical histone marks at distal regulatory
and genic regions. In contrast to previous ﬁndings in heart tissue,
expression of the pathological gene program in heart failure was
not accompanied by changes in the CM DNA methylome but by
active histone marks. In addition, our study provides a functional
map of the non-coding genome of human CMs throughout life.
Linking this functional annotation with known genetic poly-
morphisms revealed the presence of cardiovascular disease-
associated polymorphisms in active CM enhancers.
Results
Flow cytometry and sorting of human CM nuclei. To determine
the dynamics of the CM epigenome during prenatal development
and postnatal maturation as well as in disease, cardiac left ven-
tricular (LV) tissue was analyzed at three stages (fetal,
16–23 weeks of pregnancy; infant, 1–12 months of age; adult,
46–60 years) and at one disease condition of end-stage heart
failure (56–63 years, LV ejection fraction 19± 2%, Supplementary
Data 1). Fluorescence-activated sorting of cardiac nuclei was
applied to ensure CM speciﬁcity (Fig. 1a). Antibodies raised
against pericentriolar material 1 (PCM1) or signal regulatory
protein alpha (SIRPA) were used to stain postnatal CM nuclei
and fetal CMs, respectively11,14,15. These markers are highly
speciﬁc for postnatal and fetal CMs, respectively11,14,15. In addi-
tion, we identiﬁed and validated phospholamban (PLN) as a
speciﬁc marker for prenatal and postnatal CM nuclei. In the
heart, only CMs show high abundance and strong nuclear loca-
lization of PLN16,17. We conﬁrmed the validity of nuclear PLN
using dual labeling of CM nuclei with PCM1 by ﬂow cytometry
(Fig. 1b, Supplementary Figs. 1 and 2). Fetal and infantile hearts
contained a higher percentage of CM nuclei than adult hearts
(Fig. 1c). Notably, adult CM nuclei showed a higher degree of
ploidy than fetal and infantile CM nuclei (Fig. 1d). While fetal
and infantile hearts mostly contained diploid CM nuclei, the
percentage of tetraploid nuclei increased signiﬁcantly until
adulthood (Fig. 1d). Adult failing myocytes showed even a higher
proportion of polyploid nuclei (Fig. 1d).
CMs were isolated with high purity (≥98%) from LV tissue
(Fig. 1e, Supplementary Fig. 2). Puriﬁed nuclei were processed to
generate high-coverage DNA methylomes (whole-genome bisul-
ﬁte sequencing (WGBS)), 5-hydroxymethylomes (5-hydroxy-
methyl-cytosine sequencing (5hmC-seq)), proﬁles of seven
histone marks (chromatin immunoprecipitation sequencing
(ChIP-seq)) and nuclear gene expression (RNA sequencing
(RNA-seq)). All data sets were derived from independent
biological replicates (Supplementary Data 2). For nine patients,
at least six histone marks, mCpG, and nuclear RNA expression
were generated from the same samples (Supplementary Data 2).
As 5hmC-seq required higher amount of input DNA, different
biological replicates were pooled (Supplementary Data 2). In
total, we generated >3 billion mapped ChIP-seq and 60 million
5hmC-seq reads as well as 1 billion mapped RNA-seq fragments.
The cumulative CpG coverage resulting fromWGBS was 135-fold
(Supplementary Data 2). Data generated from independent
biological replicates yielded highly correlating values for ChIP-
seq (Supplementary Fig. 3), RNA-seq (Supplementary Fig. 4a),
and for mCpG (Supplementary Fig. 5). Sequencing data further
conﬁrmed the validity of the ﬂuorescence-activated cell sorting
(FACS) strategy for CM nuclei. CpG methylation data from
SIRPA-sorted cells correlated highly with data obtained from
PCM1- and PLN-sorted nuclei (Supplementary Fig. 5, correlation
coefﬁcient ≥0.95). Sequencing of nuclear RNA showed expression
of CM genes in PLN- and PCM1-positive nuclei and no
expression of non-CM genes (Supplementary Fig. 6a). RNA
proﬁles of PCM1- and PLN-sorted nuclei were highly correlated
(R2 = 0.96, Supplementary Fig. 6b).
Representative traces show a genomic region containing
troponin T2 (TNNT2) and troponin I1 (TNNI1, Fig. 1f). TNNT2
is highly expressed in CMs from fetal to adult stages and shows
sequential loss of genic mCpG and a promoter enrichment of
H3K27ac, H3K9ac, and H3K4me3 and genic enrichment of
H3K36me3 (Fig. 1f). The fetally expressed TNNI1 gene was
silenced postnatally, coinciding with genic de novo mCpG loss
and loss of active histone marks H3K27ac, H3K9ac, H3K4me3,
and H3K36me3 (Fig. 1f). Several regions with distal regulatory
domain signatures, including low mCpG and enrichment of
H3K4me1, were identiﬁed. While most of these regions seem to
be relatively stable at this genomic locus, dynamic establishment
of a distal regulatory signature occurred during CM development
in an intronic region of the plakophilin (PKP1) gene (Fig. 1f).
Next, epigenetic signatures of heart tissue18–20 and CM were
compared to get insight into cell-type speciﬁcity (Supplementary
Fig. 7). Loci containing the CM-speciﬁc myosin heavy chain α
and β genes as well as the ﬁbroblast gene biglycan21 or the
endothelial gene VE-cadherin revealed distinct differences in
mCpG and chromatin state between tissues and CMs (Supple-
mentary Fig. 7b–d). Genes that were hypomethylated in CMs vs.
heart tissue (Supplementary Fig. 7e, group 1) were involved in
cardiac muscle function (Supplementary Fig. 7f, group 1). In
contrast, genes with higher levels of mCpG in myocytes vs. heart
tissue represented developmental processes of the cardiovascular
system, vasculature, and connective tissue (Supplementary Fig. 7e,
f, group 2). Elevated mCpG was also observed in promoter
regions ﬂanking the transcription start site (TSS; Supplementary
Fig. 7g).
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Systematic analysis of CM and VISTA heart enhancers22
revealed an overlap of 49% (Supplementary Fig. 7h). VISTA
enhancers not present in CMs were adjacent to genes involved in
artery morphogenesis and collagen ﬁbril organization while CM-
speciﬁc ones were adjacent to genes related to cardiac muscle
contraction and morphogenesis (Supplementary Fig. 7i, j).
Narrowing the list of VISTA heart enhancers down to those
with conﬁrmed function in mouse embryonic hearts in vivo22
showed a 90% overlap with CM enhancers (Supplementary
Fig. 7k).
mCpG-guided annotation of genomic elements. Genomic
regions, including distal regulatory domains and genic regions,
show distinct mCpG patterns. Therefore, we segmented the
genome into partially methylated, unmethylated, and low
methylated regions (PMR, UMR, and LMR, respectively)23,24. We
identiﬁed large PMRs with highly disordered mCpG covering
43% of the genome (Supplementary Figs. 8 and 9a). PMRs
spanning large genomic domains have been observed in other
somatic cell types25 too but were not detectable in mCpG data
obtained from human heart tissues18. In agreement with previous
studies26, most CM PMRs (Supplementary Fig. 10a) showed
low levels of active histone marks (Supplementary Fig. 10b–d)
and are associated with a silent chromatin state (Supplementary
Fig. 11a, b).
Further segmentation of mCpG data resulted in UMRs and
LMRs, which covered 3% of the genome each (Supplementary
Fig. 9a). LMRs (Supplementary Fig. 10e–h) showed enrichment
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Fig. 1 Sorting and analysis of cardiac myocyte nuclei and representative epigenetic map. a Workﬂow for the isolation of human cardiac myocyte nuclei for
epigenetic and transcriptomic analysis. b FACS analysis of nuclei isolated from adult non-failing left ventricular tissue (LV). Nuclei were stained with anti-
pericentriolar material 1 (PCM1) and anti-phospholamban (PLN) antibodies to identify cardiac myocyte nuclei (red). c Proportion of cardiac myocyte nuclei
in fetal (Fe, n= 8), infantile (I, n= 5), adult non-failing (NF, n= 5), and adult failing (F, n= 5) LV tissue (mean± SEM). d Distribution of cardiac myocyte
ploidy in fetal (n= 8), infantile (n= 5), non-failing (n= 5), and failing (n= 5) left ventricles (mean± SEM). e Percentage of cardiac myocyte nuclei in LV
tissue before sorting (pre, open columns) and cardiac myocyte nuclei purity after FACS sorting (post, n= 3, mean± SEM). f Original traces of RNA
expression, mCpG, and histone marks of the troponin I type 1 (TNNI1) and troponin T type 2 (TNNT2) gene region. CpG islands, low methylated regions
(LMR), unmethylated regions (UMR), genic unmethylated regions (gUMR), and the chromatin state are annotated. Gray areas highlight differentially CpG-
methylated regions and genes. Shown are data from n biological replicates: mCpG, n= 3–5; H3K27ac, H3K9ac, H3K36me3, H3K4me1, H3K4me3,
H3K27me3, and H3K9me3, n= 3; RNA, n= 3–4; *vs. Fe, p< 0.05; ++vs. NF, p< 0.01; ***vs. Fe, ###vs. I, +++vs. NF, p< 0.001 by ANOVA
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for H3K4me1 (Supplementary Fig. 10g), depletion of H3K4me3
(Supplementary Fig. 10h), and were associated with an enhancer-
associated chromatin state (Supplementary Fig. 11a, b). Overall,
73–78% of LMRs showed an enhancer chromatin signature
(Supplementary Fig. 11d) and 55% overlap with strong enhancers
(Supplementary Fig. 11e). Genes adjacent to LMRs with enhancer
chromatin signature were signiﬁcantly higher expressed as genes
neighboring LMRs with non-enhancer chromatin state (Supple-
mentary Fig. 11e). LMRs were strongly enriched for transcription
factor motifs (Supplementary Fig. 10m) and were predominantly
found in intronic and intergenic regions (Supplementary
Fig. 10n). The ﬁve most signiﬁcantly enriched motifs contained
binding sites for the CCCTC-binding factor and transcription
factors of the myocyte enhancer factor-2 (MEF2), GATA,
TGGCA-binding protein (CTF/NF1), and T-box families (Sup-
plementary Fig. 10m).
Compared to LMRs, UMRs were larger in size (Supplementary
Fig. 10i vs. e), showed enrichment of the promoter mark
H3K4me3 (Supplementary Fig. 10l), and predominantly spanned
genic regions and annotated CpG islands (Supplementary
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Fig. 10n, o). To speciﬁcally analyze the characteristics of genes
with low methylated gene bodies, we annotated genic UMRs
(gUMR). They span genic parts overlapping with TSSs. To
eliminate a potential bias, regions overlapping with CpG islands
were excluded from gUMR annotation (Fig. 1f, Supplementary
Fig. 10o).
gUMRs in CMs. Next, we analyzed the correlation of gene
expression with inheritable marks (Fig. 2a, Supplementary
Fig. 12). Ranking of genes according to their gene expression level
revealed an inverse correlation of mCpG and gene expression
around the TSS (Fig. 2a, Supplementary Fig. 12). Analysis of
histone modiﬁcations showed a positive correlation of active
histone marks (H3K27ac, H3K9ac, H3K36me3, H3K4me1,
H3K4me3) with gene expression, while genes with very low
transcriptional activity (<1 fragments per kilobase per million
fragments mapped (FPKM)) were decorated with the inactive
marks H3K27me3 and H3K9me3 (Fig. 2a, Supplementary
Fig. 12). Comparing genes expressed (≥1 FPKM) in at least one of
the assessed stages (6515 genes, Fig. 2a) revealed that 45% were
expressed independent of age or disease. The largest number of
genes with stage-speciﬁc expression was detected in fetal CMs
(>16%, Supplementary Fig. 4b). These genes were signiﬁcantly
associated with cell cycle and chromatin organization (Supple-
mentary Fig. 4b).
The marked CpG demethylation of genic regions encouraged
us to characterize genes with extended genic CpG demethylation.
We identiﬁed 996 genes with a gUMR covering >25% or at least
5 kb of the gene (Fig. 2b, Supplementary Data 3). The majority of
these genes were marked with active histone modiﬁcations
including H3K27ac and were depleted for the polycomb mark
H3K27me3 (Fig. 2b, Supplementary Fig. 13, group I). They
showed a characteristic mCpG pattern with regions of low mCpG
overlapping with the TSS and progressing toward the 3′ end of
the gene (Fig. 2b, Supplementary Fig. 13b, group I). These genes
showed high transcriptional activity (Fig. 2b, Supplementary
Fig. 13a, group I) and include myoﬁbril proteins or are known to
be implicated in muscle structure development and muscle
structure system processes (Fig. 2b, group I, Supplementary
Data 3).
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The remaining subset of genes (Fig. 2b, group II) showed the
typical signature of inactive chromatin, including enrichment of
H3K27me3 (Fig. 2b, Supplementary Fig. 13i, j, group II) and
depletion of active histone marks (Fig. 2b, Supplementary
Fig. 13d–f, h, group II). This group of genes showed stable low
mCpG and no signiﬁcant transcriptional activity (Fig. 2b,
Supplementary Fig. 13a, group II). These genes were associated
with DNA binding and pattern speciﬁcation (Fig. 2b, group II,
Supplementary Data 3).
Dynamic gUMR mCpG in CMs. To characterize the dynamics of
genic mCpG during cardiac maturation from fetal until adult
stages and in disease, all 14,688 genes harboring a gUMR were
analyzed. From fetal life until adulthood, 529 genes exhibited
differential gUMR mCpG (DM-gUMRs) (Fig. 2c). This affected
>16,000 CpGs (Supplementary Fig. 9e). Loss of mCpG in DM-
gUMRs was associated with increased expression of genes
essential for myoﬁbril and sarcomere structures as well as reg-
ulation of contraction (Fig. 2d, group 1). In contrast, a develop-
mental increase of mCpG in DM-gUMRs was linked to decreased
gene expression and affected primarily developmental genes
(Fig. 2d, group 2). Changes in genic mCpG were accompanied by
concordant changes of histone marks (Fig. 2e). Demethylated
genic regions during maturation gained the active histone marks
H3K27ac, H3K9ac, H3K36me3, and H3K4me3 (Fig. 2e). In
contrast, hypermethylated regions showed a loss of these marks
(Fig. 2e). This illustrates the tight link of genic mCpG and histone
marks with gene expression during myocyte development and
postnatal maturation.
Development vs. maturation of gUMR mCpG. We separately
analyzed gUMR mCpG during prenatal development and post-
natal maturation (Supplementary Fig. 14). We found 29 gUMRs
that were hypomethylated and 12 gUMRs that were hyper-
methylated from fetal to infant stage (Supplementary Fig. 14a,
group I, II). Postnatally, 188 gUMRs were further demethylated
and 34 gUMRs were hypermethylated (Supplementary Fig. 14a,
groups III, IV). In all, 59% of genes that were differentially
methylated prenatally showed continuing methylation changes
postnatally. No genes with opposing mCpG changes during
prenatal vs. postnatal life were identiﬁed. We further performed a
genome-wide principal component analysis of genic mCpG. This
resulted in a trajectory from prenatal development to postnatal
maturation (Supplementary Fig. 15a). Comparable trajectories
were observed for gene expression and histone modiﬁcations
(Supplementary Fig. 15b–i). Thus mCpG developed continuously
from prenatal to postnatal life.
gUMR mCpG is stable in chronic heart failure. Remarkably,
only 6 out of the 14,688 gUMR genes were signiﬁcantly altered
(DM-gUMRs) in adult failing vs. non-failing CMs (Supplemen-
tary Fig. 16). These differences were not accompanied by con-
sistent alterations in gene expression (Supplementary Fig. 16).
Epigenetic signature of disease-associated gene expression.
Since we could not identify a clear link between DM-gUMRs and
RNA expression, we analyzed epigenetic signatures of differen-
tially expressed genes in failing vs. non-failing adult CM nuclei
(Fig. 3). For several pathologically relevant genes, including
connective tissue growth factor (CTGF) and natriuretic peptides
A and B (NPPA, NPPB), we identiﬁed concordant changes in
active histone marks (H3K27ac, H3K4me3, H3K9ac, and
H3K36me3) and gene expression in failing CMs (Fig. 3a).
However, these genes did not show overt alterations in promoter
or gene body mCpG (Fig. 3a).
To assess this on a genome-wide scale, we ranked all
differentially expressed genes in failing CM nuclei according to
the magnitude of disease-associated changes in expression
(Fig. 3b). Changes in gene expression were accompanied by
concordant alterations in active histone marks. The best
predictive marks for gene expression were H3K27ac and
H3K36me3 (Supplementary Fig. 17a, c). In combination, these
marks explained 50% of the gene expression rank (Fig. 3b, R2 =
0.509). For other histone modiﬁcations as well as for mCpG in
gUMRs (Supplementary Fig. 17) and genic regions (Fig. 3b), we
did not observe R2 values exceeding 0.14. This suggests that
disease-associated changes in gene expression primarily involve
Δ CpG methylation
(F-NF; %)
200–20
–5 kb Center of
LMR
5 kb
a
b c ed f
60
80
100 5 5 0.2
0
20
40
NF
F
–1 kb Center 
of LMR
1 kb
0
–1 kb Center 
of LMR
1 kb
0
–1 kb
Center 
of LMR 1 kb NF F
–0.2
C
pG
 m
et
hy
la
tio
n 
(%
)
H
3K
27
ac
 (
R
P
K
M
)
H
3K
4m
e1
 (
R
P
K
M
)
30
20
15
10
NF F
 N
ex
t g
U
M
R
C
pG
 m
et
hy
la
tio
n 
(%
)
NF
F
NF
F
25
Best match: NF1/CTF
–log10(p) = 13
0.0
E
xp
re
ss
io
n 
of
 n
ex
t g
en
e 
(lo
g 2
(f
ol
d 
of
 m
ea
n)
)
80
100 5 5 0.2
0
20
NF
F
–1 kb Center 
of LMR
5 kb
0
–1 kb Center 
of LMR
5 kb
0
–1 kb Center 
of LMR
1 kb NF F
–0.2C
pG
 m
et
hy
la
tio
n 
(%
)
40
60
H
3K
27
ac
 (
R
P
K
M
)
H
3K
4m
e1
 (
R
P
K
M
)
30
20
15
10
NF F
 N
ex
t g
U
M
R
C
pG
 m
et
hy
la
tio
n 
(%
)
25
No motif 
enriched
0.0
E
xp
re
ss
io
n 
of
 n
ex
t g
en
e 
(lo
g 2
(f
ol
d 
of
 m
ea
n)
)
 G
ro
up
 II
:
85
G
ro
up
 I:
28
1
mCpG
mCpG
H3K27ac
H3K27ac
H3K4me1
H3K4me1
p = 0.67
p = 0.09
p = 0.43
p = 0.43
Fig. 5 Characterization of LMRs and mCpG in heart failure. a Analysis of LMRs with differential mCpG between adult non-failing and failing cardiac
myocytes. b, c Proﬁles of mCpG (b) and histone marks (c) at DM-LMRs that are hypomethylated or hypermethylated between failing and non-failing
cardiac myocytes. d Signiﬁcantly enriched transcription factor (TF) binding motifs in hypomethylated DM-LMRs. Hypermethylated DM-LMRs (group II)
did not show signiﬁcant enrichment for TF motifs. Given are HOMER transcription factor enrichment p-values. e, f Next gUMR mCpG level (e) and relative
gene expression of adjacent genes (f) (mean± SEM). Figures show data from n biological replicates: mCpG, n= 3–5; H3K27ac, H3K4me1, n= 3; RNA,
n= 3–4
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02762-z ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:391 |DOI: 10.1038/s41467-017-02762-z |www.nature.com/naturecommunications 7
remodeling of distinct active histone modiﬁcations, while
especially repressive marks remain relatively stable.
Reconﬁguration of distal regulatory domain mCpG. Segmen-
tation of mCpG data identiﬁed >100,000 LMRs with distal reg-
ulatory properties (Fig. 4a, Supplementary Figs. 9c, 10e–h, and
11b). Of these regions, 18% (Fig. 4a, groups I+III, Supplementary
Data 4) were differentially methylated (DM-LMR) between fetal
and adult stages. The main fraction (77%) of DM-LMRs showed a
developmental loss of mCpG (Fig. 4, group I) and was strongly
enriched for transcription factor-binding motifs for CTF/NF1
and MEF2 (Fig. 4b). These DM-LMRs were located next to genes
essential for cardiac contraction and energy supply (Fig. 4c). In
contrast, DM-LMRs with increasing mCpG in adult vs. fetal CMs
(Fig. 4a, group III) were enriched for DNA sequences similar to
known motifs of GATA, TEAD, and T-box transcription factors
(Fig. 4d). These DM-LMRs were adjacent to genes involved in
general and muscle-speciﬁc early developmental and differentia-
tion processes (Fig. 4e).
Loss of mCpG in DM-LMRs was accompanied by an increase
of the active histone marks H3K27ac and H3K4me1 and a
concordant decrease of H3K27me3 enrichment (Fig. 4f, group I).
These DM-LMRs were associated with neighboring genes that
lost gUMR methylation and showed increased expression (Fig. 4g,
h, group I). CpG demethylation of these DM-LMRs was preceded
by establishment of 5hmC at the center of the nascent LMRs
indicating an active TET-dependent demethylation (Fig. 4f, group
I). LMRs with stable mCpG showed a relatively constant level of
histone marks, gene expression of neighboring genes, and their
gUMR mCpG (Fig. 4f–h, groups II). LMR-diffentially methylated
regions (DMRs) with increased mCpG from the fetal to the adult
stage contained a primarily inactive histone signature as
illustrated by high H3K27me3 and low H3K4me1 as well as
H3K27ac signals (Fig. 4f, group III). Neighboring genes showed
an increase in genic mCpG and a decrease in gene expression
(Fig. 4g, h, group III). This demonstrates an interplay of mCpG
and histone marks at regulatory domains and their inﬂuence on
transcriptional activity during development and maturation of
CMs.
Development vs. maturation of mCpG of LMRs. Comparing
LMRs during prenatal development and postnatal maturation
indicated that loss of mCpG prevails in postnatal CMs (7160
hypomethylated vs. 693 hypermethylated DM-LMRs, Supple-
mentary Fig. 14b). During development, the number of DM-
LMRs with loss or gain of mCpG were comparable (Supple-
mentary Fig. 14b). We found a similar set of transcription factor
motifs to be enriched in DM-LMRs during the prenatal and
postnatal periods (Supplementary Fig. 14c). Comparing devel-
opment and maturation, only 0.36% (35) of DM-LMRs showed
opposing mCpG (not shown).
LMRs in heart failure. Next, we analyzed DM-LMRs of adult
failing vs. non-failing CM nuclei (Fig. 5). Heart failure affected
the mCpG levels of 3647 CpGs within 366 DM-LMRs (Fig. 5a,
Supplementary Fig. 9c). The extent of mCpG changes was >45-
fold smaller in disease as compared to development (176,630
CpGs within 18,095 DM-LMRs) (Supplementary Fig. 9c).
DM-LMRs with a disease-associated loss of mCpG showed a
tendency for higher levels of H3K27ac and H3K4me1 (Fig. 5b, c,
group I). These DM-LMRs were enriched for sequences similar to
the transcription factor motif of CTF/NF1 (Fig. 5d, group I).
Genes adjacent to these DM-LMRs showed stable genic mCpG
(Fig. 5e, group I) and gene expression (Fig. 5f, group I). GREAT
analysis27 of these genes did not reveal an association with cardiac
gene programs. We identiﬁed 85 DM-LMRs with increasing
mCpG in adult failing as compared with non-failing CMs (Fig. 5a,
b, group II). These DM-LMRs did not show changes of active
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histone marks (Fig. 5c, group II), gUMR mCpG, or gene
expression of adjacent genes (Fig. 5e, f). This indicates that
disease-associated alterations of mCpG are rare and not directly
linked to alterations of other inheritable marks or gene
expression.
Enrichment of genetic variants in LMRs. Cardiac cis-regulatory
regions contain disease-associated single-nucleotide polymorph-
isms (SNPs)28. To test whether genetic variations map to LMRs in
CMs, we analyzed SNPs linked with different disease traits. SNPs
associated with cardiac arrhythmia or coronary heart disease were
most signiﬁcantly enriched in CM LMRs (Fig. 6a). SNPs asso-
ciated with congenital heart disease were also enriched in LMRs,
but this association did not reach statistical signiﬁcance (Fig. 6a).
SNPs associated with diseases in other organ systems showed
smaller or no enrichment in CM LMRs (Fig. 6a). LMRs associated
with disease SNPs showed a very low overlap between cardiac
arrhythmia, coronary heart disease, and non-cardiovascular dis-
ease, respectively (Fig. 6b). GREAT analysis identiﬁed that LMR
regions associated with cardiac arrhythmia were enriched for
genes involved in cardiac excitation and conduction or cardiac
contraction (Fig. 6c). Disease-associated LMRs showed char-
acteristics of cis-regulatory regions, including enrichment of
H3K4me1 and H3K27ac (Fig. 6d, e). These regions showed
increasing H3K27ac levels (Fig. 6e) and a signiﬁcant loss of
mCpG (Fig. 6f) from fetal to adult stages. This indicates that
genetic polymorphisms that are linked with cardiac disease traits
are enriched in cis-regulatory regions of CMs.
Discussion
Here we present epigenome maps of human CMs during prenatal
development, postnatal maturation, and in chronic heart failure.
Our data reveal a highly dynamic interplay between mCpG and
histone modiﬁcation to shape the CM transcriptome during
development and maturation (Fig. 7). In chronic heart failure,
mCpG of genic and cis-regulatory regions was remarkably stable.
Pathological gene expression was accompanied by changes of
active histone marks (Fig. 7). Furthermore, the signiﬁcant
enrichment of genetic polymorphisms that have been linked with
cardiac disease underlines the pathological relevance of active cis-
regulatory elements in CMs (Fig. 7).
Several studies highlight the importance of cell-type-speciﬁc
epigenomic analyses29. However, isolation of CMs from human
hearts is challenging. In 2009, Bergmann et al. described a tech-
nique to isolate CM nuclei using speciﬁc protein markers,
including PCM1, to study CM proliferation in human hearts13,14.
The speciﬁcity of PCM1 to label postnatal CM nuclei has been
characterized extensively for mouse and human hearts11,12,14.
SIRPA has been used previously as a marker of fetal CMs15. Here
we use a common marker for both prenatal and postnatal CM
nuclei, PLN30. The speciﬁcity and validity of PLN is strongly
supported by immunohistochemical staining16 and by experi-
mental evidence provided in the present study. Labeling of car-
diac nuclei with anti-PLN antibodies enables identiﬁcation and
puriﬁcation of CM nuclei from prenatal and postnatal human
hearts.
Our genome-wide analysis of mCpG identiﬁed genic regions
with unmethylated CpGs (gUMR)22,23,33. In concordance with
previous studies11,31,32, depletion of mCpG affected transcribed
regions extending from the TSS toward the 5′ end of genes. Low
levels of mCpG correlated with higher levels of active histone
marks and gene expression. Analysis of fetal, infantile, and adult
non-failing data sets revealed dynamic genic mCpG during pre-
natal and postnatal development affecting 10% of all genes har-
boring a gUMR. Alterations within these genes were also present
on the layer of histone modiﬁcations and gene expression and
affect especially genes involved in the maturation of CMs.
Notably, the negative correlation between mCpG and gene
expression was not observed for a large group of early develop-
mental genes that were marked with H3K27me3. These genes
showed low mCpG despite very low transcriptional activity.
Intriguingly, low mCpG was not restricted to genic regions for
these genes but extended into surrounding genomic regions,
which have previously been termed mCpG valleys33.
Recent studies show that regions with low mCpG (LMR) have
cis-regulatory properties23,24,34,35. In myocyte nuclei, we
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Fig. 7 Dynamics of mCpG and histone modiﬁcations in gene bodies and enhancer regions of cardiac myocyte genes during heart development and in
chronic heart failure. During cardiac myocyte development, mCpG of enhancers (LMR low methylated region, Fig. 4) and genic regions (gUMR genic
unmethylated region, Fig. 2) and canonical histone marks cooperate to induce (MYH6, RYR2, TNNI3) or repress (MYL4, NPPA, TNNI1) cardiac myocyte
genes (left panel, Fig. 1f). In failing cardiac myocytes (right panel), induction of disease-associated genes is accompanied by active histone marks without
changes in gene body mCpG (Fig. 3b). Some LMRs showed small changes in mCpG in heart failure (Fig. 5a). Low methylated regions with enhancer
signature were signiﬁcantly enriched for single-nucleotide polymorphisms (SNP), which have been linked with cardiac disease (Fig. 6)
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identiﬁed >100,000 LMRs. The high degree of cell-type speciﬁcity
of cis-regulatory domains with low mCpG is underlined by the
strong enrichment of cardiac transcription factor motifs within
these regions. Notably, motifs of different transcription factors
were clustered within most cis-regulatory regions. The most
prevalent combinations include T-box, GATA, or MEF2 motifs.
Co-occupancy of these and other cardiac transcription factors has
been described previously using a murine atrial cardiac muscle
cell line36 and in vitro differentiated mouse CMs4. Alternatively,
enhancers can be identiﬁed based on chromatin marks. Chro-
matin mark-based prediction using ChromHMM37 identiﬁed
216Mb with strong enhancer signature in CMs. Cis-regulatory
regions like LMRs represent either active enhancers or silent as
well as repressive elements. We found a large overlap between cis-
regulatory regions identiﬁed as LMRs and enhancers predicted by
chromatin marks.
These ﬁndings support that localized low mCpG is a hallmark
of cis-regulatory regions23,24,34,38. Establishment of LMRs has
been shown to depend on transcription factor occupancy24,39.
LMRs show lowest mCpG values at accessible sites as revealed by
parallel analysis of mCpG and accessibility in single cells34,40. Cis-
regulatory sites marked by low mCpG can act as enhancers or
silencers (Fig. 1f, gray highlighted LMRs). Chromatin state
annotation using histone marks is important for the identiﬁcation
of the activation state. Chromatin modiﬁcations are deposited at
histones ﬂanking transcription factor-binding sites41. Combining
ChIP-seq and WGBS will likely improve the prediction of loca-
lization and activation state of cis-regulatory regions. A recent
study invented an algorithm integrating ChIP-seq and WGBS
data for prediction of tissue-speciﬁc enhancers35.
Comparing our data with a recent study reporting >80,000
putative enhancers (264Mb) in mouse and human prenatal and
postnatal hearts22 revealed that 17% of enhancers detected in the
hearts do not overlap with enhancers detected in CM. These
“heart-speciﬁc” enhancers were situated near genes associated
with non-CM functions. Looking at in vivo conﬁrmed VISTA
heart enhancers22, the overlap with CM enhancers is 90%. Thus
our study provides a comprehensive annotation and character-
ization of cis-regulatory regions in human CMs.
During prenatal development and postnatal maturation, >18%
of CM cis-regulatory regions identiﬁed as LMRs showed differ-
ential mCpG. Concordant gene expression and gUMR mCpG
changes of adjacent genes suggest the functional relevance of
these cis-regulatory sites. Affected genes were implicated in
development and maturation of CMs highlighting the biological
relevance of these observations. Regions gaining mCpG showed
signiﬁcant enrichment of motifs related to the GATA, T-box, and
TEAD families. A similar combination of motifs has previously
been found in murine HL-1 cells36. In contrast, loss of mCpG
affected regions containing MEF2 and CTF/NF1 motifs. mCpG
changes were associated with concordant changes in histone
modiﬁcations. Notably, regions gaining mCpG during develop-
ment already showed low levels of enhancer marks at the fetal
stage. This may indicate that changes at the chromatin level
precede altered mCpG. These differences in kinetics of histone
modiﬁcations and mCpG have previously been observed during
mouse organ development and were termed “epigenetic mem-
ory”42. In addition, regions losing mCpG were pre-marked with
5hmC, indicating active CpG demethylation43. These results
clearly show that developmental mCpG of cis-regulatory sites is
actively modiﬁed after lineage decision and orchestrates with
dynamic modiﬁcation of histones and gene expression.
Comparison of mCpG changes during development of fetal
and maturation of infantile CMs revealed a continuum with
predominant loss of mCpG. In contrast, a recent study44 ana-
lyzing prenatal and postnatal mCpG dynamics in mouse organs,
including heart, reports that continuous loss of mCpG at
enhancer regions dominates prenatal development, while gain of
mCpG is characteristic for postnatal stages. One reason for this
discrepancy could be the different developmental stage of mice
and men at birth. Another reason could be a postnatal change in
cellular composition. In case of the heart, fetal and infantile hearts
predominantly consist of CMs. After birth, CMs loose cell cycle
activity. In contrast, endothelial and mesenchymal cell pro-
liferation augments after birth14. This results in an approximately
50% lower proportion of CM nuclei in adult as compared to
prenatal mouse11 and human hearts (Fig. 1c). The resulting
increasing postnatal cellular complexity may mask cell-type-
speciﬁc LMRs leading to the predominant detection of a gain of
methylation in tissues after birth.
The interplay of epigenetic signatures and gene expression that
we observed during development was not evident in chronic heart
failure. Only six genes showed differential mCpG at their gene
body between non-failing and failing CMs. Of those, none
showed a statistically signiﬁcant differential expression. Also
LMRs with cis-regulatory properties showed a very low degree of
disease-associated mCpG changes. Strikingly, these alterations
were not associated with an altered chromatin state and were not
found near to differentially expressed genes. Thus mCpG remains
relatively stable in chronic heart failure.
However, pathological gene expression in failing CMs was
signiﬁcantly linked with levels of active histone marks. These data
are consistent with recent observations on the role of bromodo-
main proteins in the heart, which recognize acetylated his-
tones45,46. Blockade of the bromodomain protein Brd4 by small
molecule compounds inhibited pathological gene expression and
progression of heart disease in a mouse model of cardiac pressure
overload and in CMs in vitro45,46. A recent series of publica-
tions47–49 reports a regulatory role of the histone mark
H3K9me2, a mark not studied in this project. Future studies are
necessary to show whether the proposed mechanisms are
involved in human heart failure.
Genome-wide association studies for multiple diseases have
identiﬁed a plethora of disease-associated variants in the non-
coding genome50,51. Many of these genetic variants were mapped
to loci with regulatory properties, including enhancers52. Recent
comprehensive studies have generated genome-wide enhancer
maps of heart tissue and have linked speciﬁc enhancer regions
with genetic variants associated with myocardial repolarization
and conduction28 and other forms of cardiac disease22. However,
these studies do not address in which cardiac cell type and
developmental or disease state disease-associated enhancers exist.
The present study identiﬁed >100,000 LMRs with cis-regulatory
signatures. Genetic variants that have previously been linked with
cardiac arrhythmia, coronary, or congenital heart disease were
enriched in these regions in CMs. Notably, SNP-bearing LMRs
were strongly associated with genes, which have previously been
identiﬁed in genetic forms of cardiac channelopathies, including
pacemaker channels (HCN4—Brugada syndrome), multiple K+
channels (KCNE1, KCNH2, KCNJ2, KCNQ1—long and short QT
syndromes), and voltage-gated Na+ channels (SCN5A—Brugada
syndrome, sick sinus syndrome)53. Further studies are needed to
directly link enhancers containing genetic variants with CM
genes.
The present study identiﬁes mCpG and histone modiﬁcations
as connected or separate layers of epigenetic regulation during
human CM development and disease, respectively. This detailed
insight into the CM epigenome in intact human hearts will be
important for several areas of research. First, this CM epigenome
may serve as a roadmap for further studies in embryonic stem
cells or induced pluripotent stem cells to generate mature CMs
in vitro for cell therapy of heart disease and for direct
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reprogramming of cells into CM in vivo. Second, our epigenetic
data enable functional annotation of non-coding regions of the
genome in CMs. This will be important to unravel the genetics of
cardiac disease in non-coding regions of the genome. Further
epigenetic studies of other cardiac cell types will help to better
understand the contribution of individual cell types to cardiac
disease. Third, this CM epigenome provides comprehensive
insight into the molecular marks that are associated with phy-
siological and pathological gene expression in CMs. Future stu-
dies mapping the three-dimensional architecture, protein
complexes, and non-coding RNAs will help to develop new
strategies for treatment of heart disease.
Methods
Human cardiac biopsies. LV biopsies from male hearts were used for CM nuclei
isolation. These investigations were approved by the ethics committees of the
Mount Sinai School of Medicine (New York, USA) and the Universities of Frei-
burg, Jena and Munich (Germany) (Suppl. Table 1) with informed consent of
human participants. All samples retrieved during interventions (fetal and failing as
well as rejected donor hearts) were immediately ﬂash frozen and stored at −40 to
−80 °C. Tissue from accidentally killed patients was ﬂash frozen during the autopsy
not later than 24 h after death. To comply with the ethics committee approval, we
unassigned patient information and genomic sequence information (Supplemen-
tary Data 1 and 2).
FACS of CM nuclei. All steps were performed at 4 °C to ensure integrity of
chromatin and RNA. For nuclear RNA isolation RNAsin (80 U/ml, Promega) was
added to all buffers. Isolated nuclei were stained in 500 µl staining buffer (phos-
phate-buffered saline (PBS) containing 1 % bovine serum albumin (BSA), 22.5 mg/
ml glycine, 0.1% Tween 20) using anti-PCM1 (1:500, HPA023370, Sigma) and anti-
PLN antibodies (1:500, A010–14, Badrilla) for 30 min. For isotype control stain-
ings, we used primary antibodies lacking target speciﬁcity (1:1000, anti-mouse,
554121, BD; 1:1000, anti-rabbit, Z25308, Life technologies). Subsequently, the
corresponding Alexa488- and Alexa568-labeled secondary antibodies (1:1000,
A11029 and A11011, Invitrogen) were added. After 30 min of incubation, nuclei
were pelleted by centrifugation (1000 × g, 5 min) and resuspended in 1 ml PBS
containing 1 mM ethylenediaminetetraacetic acid (EDTA). Nuclei were ﬁltered
(CellTrics 30 µm, Sysmex) and incubated with Draq7 (ﬁnal concentration 2.25 nM,
Cell Signaling) for 10 min. Nuclei were analyzed (Bio-Rad S3, Bio-Rad; LSRFor-
tessa, BD) and sorted by ﬂow cytometry (Bio-Rad S3, Bio-Rad).
FACS of fetal CMs. Human fetal heart tissue was cut into small pieces and
incubated in collagenase type II (1 mg/ml; Worthington) in Hanks solution (NaCl,
136 mM; NaHCO3, 4.16 mM; NaPO4, 0.34 mM; KCl, 5.36 mM; KH2PO4, 0.44 mM;
dextrose, 5.55 mM; HEPES, 5 mM) for 6 h at 37 °C with gentle shaking. After
incubation, cells were centrifuged (250 × g, 5 min) and the supernatant was
removed. BSA 1mg/ml in PBS-Ca2+/Mg2 solution was added to the cellular pellet
and was pipetted gently to dissociate the cells. After dissociation, cells were ﬁltered
and used for analysis. Cells were stained in ice for 1 h at a concentration of 2.5 ×
106 cells/ml with anti-SIRPA-IgG-phycoerythrin-Cy7 (clone SE5A5; BioLegend;
1:100) and anti-CD90-allophycocyanin (clone: 5E10; BD Pharmingen; 1:100). For
FACS, the cells were sorted at a concentration of 106 cells/ml in PBS-Ca2+/Mg2
with 10% fetal bovine serum using an Aria II cell sorter (BD Biosciences). To
prevent cell death due to pressure and sheer stress, all sorts were performed with a
100-μm nozzle.
Chromatin immunoprecipitation sequencing. Isolated CM nuclei were ﬁxed with
paraformaldehyde (ﬁnal concentration 1 %, Thermo Fisher) for 2 min at room
temperature. Fixation was quenched by adding glycine to a ﬁnal concentration of
0.125 M. Nuclei were washed twice with washing buffer (50 mM Tris-HCl pH 8.0,
10 mM EDTA) supplemented with protease inhibitors (cOmplete Protease Inhi-
bitor Cocktail, Roche). After addition of sodium dodecyl sulfate to a ﬁnal con-
centration of 1%, nuclei were incubated for 10 min. Chromatin was sonicated using
a Bioruptor (Diagenode) with 30 cycles (30 s on followed by 30 s off; high energy).
After centrifugation (13000 × g, 10 min), the chromatin containing supernatant was
used for ChIP experiments. The amount of chromatin (measured as DNA) was
quantiﬁed using a Qubit 2.0 ﬂuorometer (Life Technologies) and the corresponding
Qubit dsDNA HS Assay Kit (Life Technologies). In all, 100–200 ng of isolated
chromatin was used for ChIP experiments. Immunoprecipitation, reversal of cross-
linking, and DNA puriﬁcation were performed using the ChIP-IT High Sensitivity
Kit (Active Motif) following the manufacturer’s manual and the antibodies listed in
Supplementary Table 1. The eluted DNA (200 µl) was concentrated by evaporation
at room temperature using a vacuum concentrator (Eppendorf) to 55.5 µl. Libraries
were prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina (NEB)
according to the manufacturer’s manual omitting the size selection. Library
ampliﬁcation was monitored after addition of Eva Green (1:20, #31000, Biotium)
by quantitative PCR (qPCR) using a real-time PCR cycler (Stratagene) and stopped
after the turning point of the ampliﬁcation curve was reached. Libraries were
sequenced on Illumina sequencers in paired-end mode.
Nuclear RNA sequencing. Nuclear RNA was extracted from sorted nuclei using
either the RNeasy Micro Kit or the AllPrep DNA/RNA Micro Kit (Qiagen)
including on-column DNAse digestion. RNA was reverse transcribed and ampliﬁed
with the Nugen Ovation RNA-seq System V2 (Nugen). The resulting cDNA was
fragmented (Bioruptor, Diagenode). Sequencing libraries were constructed from
100 ng fragmented cDNA using the NEBNext Ultra DNA Library Prep Kit (NEB).
The necessary PCR cycles were determined by qPCR after addition of Eva Green
(Biotium). RNA-seq libraries for direct comparison of PLN- and PCM1-positive
nuclei were prepared using the NEBNext Ultra RNA Library Prep Kit for Illumina
(NEB) in combination with the RiboMinus Eukaryote System v2 (Life Technolo-
gies)12. All libraries were sequenced on Illumina sequencers in paired-end mode.
Whole-genome bisulﬁte sequencing. WGBS-seq libraries were constructed from
250 ng DNA using the Ovation Ultralow Methyl-Seq Library System (Nugen) or
from 0.5–1.5 µg DNA using the NEXTﬂex Bisulﬁte-Seq Kit (Bioo). For small DNA
amounts between 5 and 30 ng from sorted fetal CMs, a tagmentation-based pro-
tocol (T-WGBS)54 was chosen. Libraries were sequenced on Illumina sequencers in
paired- or single-end mode.
5hmC sequencing. DNA was extracted from sorted nuclei using the AllPrep DNA/
RNA Kit (Qiagen). DNA was sheared in a volume of 100 µl at low intensity for 30
cycles (30 s on followed by 90 s off) using a Bioruptor (Diagenode). Sheared DNA
was processed using the hydroxymethyl Collector–Seq Kit (Active Motif) according
to the manufacturer’s instructions. The resulting DNA was used for library gen-
eration using the NEBNext Ultra DNA Library Prep Kit (NEB). Libraries were
sequenced on Illumina sequencers in paired-end mode.
Gene ontology (GO). To identify enriched GO terms in the categories “biological
process”, “cellular component” and “molecular function” ClueGO55 was used.
Bonferroni step-down correction was performed for multiple testing-controlled p-
values. The GO term connectivity threshold was adjusted to 0.3 (kappa value) and
only pathways with a p-value ≤ 0.01 were considered as signiﬁcant. The resulting
terms were functionally grouped and illustrated, whereby the most signiﬁcant term
in each group was selected as leading term.
Processing of sequencing reads and mapping. All bioinformatics tools used to
analyze sequencing data were integrated in the Galaxy platform56. Quality and
adapter trimming of sequencing reads was performed prior to mapping to remove
low quality reads and adapter contaminations. RNA-seq data were mapped to the
human genome (hg19) using Tophat257. ChIP-seq and 5hmC-seq data were
mapped using Bowtie258 and WGBS-seq using Bismark59. PCR duplicates were
removed using SAMtools60. Quality and adapter trimming of sequencing reads was
performed prior to mapping to remove low quality reads and adapter con-
taminations. RNA-seq data were mapped to the human genome (hg19) using
Tophat257. PCR duplicates were removed using SAMtools60.
RNA-seq data analysis. Owing to the high number of intronic reads arising from
unspliced RNAs in nuclear RNA-seq data12,61, we used intronic and exonic regions
of coding genes for gene expression analysis. Mapped RNA fragments were further
processed using Cuffnorm62 to calculate FPKM values as an estimate of transcript
expression. For differential gene expression, HTSeq count63 and Deseq264 were
used. A q-value of <0.05 was considered as signiﬁcant. Genes with expression
values of <3 FPKM in all the compared groups were excluded from the differential
gene expression analysis. We used Cufﬂinks62 to determine the main transcription
start (TSS) and stop site (TES) of each coding gene using merged RNA-seq data
from all assessed stages. To exclude biases, we analyzed alternative usage of TSS
and TES sites using Cuffdiff62 and did not observe signiﬁcant differences between
fetal, infant, adult non-failing, and adult failing CMs.
Correlation of gene expression and epigenetic marks. For a comparison of
differential gene expression with results obtained from ChIP-seq and WGBS, genes
differentially regulated in failing as compared to non-failing hearts were ranked
according to fold changes (log2(F/NF)). This ranking was applied to data obtained
from ChIP-seq and WGBS. WGBS data were used to calculate differential mCpG of
gUMRs and genic regions of the ranked genes (F–NF). The ratio of ChIP-seq data
(F/NF) was calculated using bamCompare65. For quantiﬁcation of H3K27ac,
H3K9ac and H3K4me3 promoters (TSS ± 1 kb) and for H3K36me3, H3K9me3,
H3K27me3, and H3K4me1 genic regions (TSS to TES) were used.
ChIP-seq and 5hmC data analysis. Sequencing data were processed using
DeepTools65. For comparison of different data sets, read counts were normalized to
the geometric mean of the genome-wide read count. This normalization was
performed for the different analyzed features (i.e., gUMRs, LMRs). To combine
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results of different histone modiﬁcations, the normalized ratios of the individual
marks were averaged on a logarithmic scale. For visualization, we merged the
results of biological replicates.
ChrommHMM. ChromHMM37 was used to learn a 10-state model predicting
chromatin states based on ChIP-seq data from non-failing adult CMs. For the
annotation of chromatin states in CMs, we used ChIP-seq data generated for
H3K27ac, H3K9ac, H3K36me3, H3K4me1, H3K4me3, H3K9me3, and H3K27me3.
For comparison of chromatin states in adult CMs and heart tissues, we used the
same ChIP-seq data from adult non-failing CMs except for H3K9ac, since these
data are not available from Encode or Roadmap18–20. The derived states were
classiﬁed as enhancer (H3K4me1, H3K9/27ac), promoter (H3K4me3), transcribed
chromatin (H3K36me3), bivalent chromatin (H3K4me3, H3K27me3), hetero-
chromatin (H3K9me3), polycomb repressed chromatin (H3K27me3), and silent
undeﬁned chromatin (no enriched chromatin mark).
External data. Cardiac enhancers (predicted VISTA heart enhancers) derived from
>35 human and mouse H3K27ac and p300 data sets were obtained from Dickel
et al.22. In vivo conﬁrmed VISTA heart enhancers were also obtained from Dickel
et al.22. For comparison of CM data with published heart data sets, we reanalyzed
WGBS (adult 34 years, Encode number ENCSR579AXB; 3 years' infant LV,
ENCSR012TGL; 101 day fetal heart, ENCSR699ETV), and ChIP-seq data (34 years'
adult LV: H3K9me3, ENCSR176KNR; H3K4me1, ENCSR111WGZ; H3K36me3,
ENCSR434MDA; H3K27ac, ENCSR150QXE; H3K4me3, ENCSR487BEW,
H3K27me3, ENCSR503YOF) generated by the Encode and Roadmap consortia18–
20.
mCpG analysis. mCpG data were extracted from mapped reads and data of both
strands were merged using MethylDackel (https://github.com/dpryan79/
MethylDackel). For segmentation20,21, we merged the replicates of the different
stages to increase the coverage. In brief, genomic regions with highly disordered
mCpG (PMRs) were identiﬁed using a 101 CpG sliding window with a step size of
1 CpG. A two-state Hidden-Markov model identiﬁed PMRs based on the deviation
of methylation level distributions from the typical polarized distribution, which
favors high and low methylation. Neighboring PMR segments were fused. After
masking of PMRs, we smoothed the mCpG data using a running window of three
CpGs to reduce noise. To identify suitable parameters (minimal number of CpGs
and mCpG cut-off) for the identiﬁcation of hypomethylated regions, we calculated
the false discovery rate (FDR) by comparing the number of identiﬁed regions in the
original and a randomized methylome. For all methylomes generated in this study,
at least 3 CpGs and a mCpG of ≤50% was chosen as parameter for the detection of
hypomethylated sites. These parameters ensured in all assessed methylomes an
FDR< 5%. We used a cut-off of 30 CpGs to discriminate LMR and UMR (LMRs<
30 CpGs, UMRs ≥ 30 CpGs)20,21. This cut-off clearly separated CpG-low regions
with methylation levels between 10 and 50% (LMRs) from un-methylated CpG-
rich regions (UMRs)20,21.
Since the segmentation result is inﬂuenced by the local sequencing depth and
surrounding mCpG variability, we merged the segments of the different stages
using MergeBED66 to obtain a comprehensive set of CM LMRs, UMRs, and PMRs.
These regions were used for all further steps. The high degree of UMRs overlapping
genic regions prompted us to deﬁne gUMRs. Since genic demethylation is initiated
at the TSS and progresses toward the 5′ region of the gene, gUMRs overlap with the
TSS. Only genes spanning at least 1.5 kb outside of CpG islands were used for this
assignment. Finally, CpGs overlapping with annotated CpG islands67 were
removed to obtain gUMRs. Genes with distinct low genic mCpG fulﬁlled the
following criteria. They harbor a gUMR of at least 5 kb and/or the gUMRs overlap
with at least 25 % of the gene. An additional prerequisite is that the gUMRs consist
of at least 10 CpGs. Fully methylated regions (FMRs) represent genomic regions
not overlapping with CpG islands, LMRs, UMRs, and PMRs.
Replicate-based differential methylation analysis (replicate DMR) was
performed using Metilene68 for FMRs, CpG islands, LMRs, gUMRs, and PMRs.
Since genic regions downstream of gUMRs were frequently partially methylated
too, PMRs overlapping a single gene to at least 75% were removed from differential
methylation analysis. For the analysis of differential mCpG, we used the results
obtained from the individual biological replicates. A difference of >10% and a p-
value ≤ 0.001 was considered as signiﬁcant. A minimal coverage of one in all
compared samples was required to include a CpG in the statistical analysis.
Biological replicates with a median CpG coverage of ≤4 were excluded from the
statistical analysis.
For the identiﬁcation of DMRs between adult heart tissue and CMs, we used the
binary segmentation algorithm implemented in Metilene68. For this analysis, we
used Encode data from human left ventricle and compared it with the merged data
obtained from CM nuclei from non-failing adult hearts. A difference of >10 % and
a p-value ≤ 0.001 was considered as signiﬁcant. DMRs spanning <10 CpGs were
rejected.
For visualization, we merged the results of biological replicates and smoothened
the data using a running average of three CpGs.
General bioinformatic analysis. We used Homer69 to perform a de novo motif
analysis using the “size given” option. GREAT27 was used to identify genes in
proximity (≤10 kb) to LMRs and to annotate genes within regulatory domains of
SNPs. DeepTools65 and HiCExplorer70 were used to display traces and heatmaps
and to perform cluster analysis. Annotations and genome ﬁles (hg19) were
obtained from the UCSC71. Prism 5 (GraphPad) was used for statistical analysis
and graphs.
SNP identiﬁcation. Disease-associated SNPs were obtained from the NHGRI-EBI
GWAS catalog for different traits on September 30, 201672. Search terms were:
cancer, digestive system disease, immune system disease, metabolic system disease,
nervous system disease, and hypertension. In addition, we searched and combined
loci retrieved for the search terms congenital heart and heart malformation
(combined term: congenital heart disease), myocardial infarction, and coronary
heart disease (combined term: coronary heart disease) as well as heart rate, PR
interval, QT interval, and cardiac arrhythmia (combined term: cardiac arrhythmia).
Duplicate SNPs were removed. SNAP73 was used to retrieve proxy SNPs in linkage
disequilibrium (R2> 0.8, CEU population, 1000 Genomes, Pilot 1)72 with the lead
SNPs.
Data availability. All sequencing data sets reported in this manuscript are
deposited in the Short Read Archive at the National Center for Biotechnology
Information under the BioProject ID PRJNA353755. Additional data that support
the ﬁndings of this study are available from the corresponding author upon
request.
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